Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 37.32% ...

Fintel reports that on January 23, 2025, Roth MKM initiated coverage of Innventure (NasdaqGM:INV) with a Buy recommendation.

Roth MKM analyst Scott Stember maintained a Hold rating on Polaris (PII – Research Report) today and set a price target of $57.00. The ...

Rohit Kulkarni, Roth MKM managing director, joins 'Squawk on the Street' to discuss how the ban of TikTok impacts the social ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 29.90% ...

In a report released today, Scott Stember from Roth MKM maintained a Buy rating on Brunswick (BC – Research Report), with a price target of ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

HB Wealth Management LLC increased its position in shares of Snap-on Incorporated (NYSE:SNA – Free Report) by 16.4% during ...

Roth MKM keeps a Buy rating on Imax (IMAX) with a $28 price target after the company signed an exclusive, worldwide deal with ...

Roth MKM keeps a Buy rating and $38 price target on Digi International (DGII) following its non-deal roadshow with the management team. The firm comes away from the discussions “cautiously ...

Roth MKM last night initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $29 price target Entrada is an early-stage biopharma that seeks to solve a key bottleneck, which is ...

Roth MKM lowered the firm’s price target on Mattel (MAT) to $20 from $21 and keeps a Neutral rating on the shares ahead of ...